Marrying Immunotherapy with Chemotherapy: Why Say IDO?
- 15 September 2005
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (18), 8065-8068
- https://doi.org/10.1158/0008-5472.can-05-2213
Abstract
Activation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facilitates immune escape. A recent study now shows how small-molecule inhibitors of IDO can be used to leverage the efficacy of traditional chemotherapeutic drugs that are used to treat cancer in the clinic. By promoting antitumor immune responses in combination with cytotoxic chemotherapy, IDO inhibitors may offer a drug-based strategy to more effectively attack systemic cancer.Keywords
This publication has 30 references indexed in Scilit:
- CD4+CD25+ Regulatory Lymphocytes Induce Regression of Intestinal Tumors in ApcMin/+ MiceCancer Research, 2005
- GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-DioxygenaseImmunity, 2005
- Immunotherapy and chemotherapy — a practical partnershipNature Reviews Cancer, 2005
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004
- T cell apoptosis by tryptophan catabolismCell Death & Differentiation, 2002
- CTLA-4–Ig regulates tryptophan catabolism in vivoNature Immunology, 2002
- Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanismsOncogene, 1999
- BIN1 is a novel MYC–interacting protein with features of a tumour suppressorNature Genetics, 1996
- Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activityNature, 1974